Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 575-578

  Furtado, Michelle ^a   Dyer, Martin J S ^b   Johnson, Rod ^c   Berrow, Margie ^d   Rule, Simon ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c St James's Institute of Oncology   (United Kingdom)

^d PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

CD20 antibody; Mantle cell lymphoma; Ofatumumab

Indexed keywords

OFATUMUMAB; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONJUNCTIVITIS; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SWELLING; TREATMENT DURATION;

CD20 ANTIBODY; MANTLE CELL LYMPHOMA; OFATUMUMAB;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FATIGUE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84899473410     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12769     Document Type: Article

References (10)

1. Bleeker, W.K., Munk, M.E., Mackus, W.J.M., van den Brakel, J.H.N., Pluyter, M., Glennie, M.J., van de Winkel, J.G.J. & Parren, P.W.H.I. (2007) Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. British journal of haematology, 140, 303-312.
2. Coiffier, B., Lepretre, S., Pedersen, L.M., Gadeberg, O., Fredriksen, H., van Oers, M.H.J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J., Flensburg, M., Petersen, J. & Robak, T. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 111, 1094-1100.
3. Coiffier, B., Bosly, A., Wu, K.L., Verhoef, G., Koen, V.E., Martinelli, G., Barca, G., Davies, A., Padmanabhan, S., Gallop-Evans, E., Gupta, I.V., Lin, T.S., Davis, R.L., Losic, N., Lisby, S. & Radford, J.A. (2010) Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter phase II study. Blood (ASH Annual Meeting Abstracts), 116, 3955.
4. Czuczman, M.S., Hess, G., Gadeberg, O.V., Pedersen, L.M., Goldstein, N., Gupta, I., Jewell, R.C., Lin, T.S., Lisby, S., Strange, C., Windfeld, K. & Viardot, A. (2012) Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. British journal of haematology, 157, 438-445.
5. Foran, B.J.M., Rohatiner, A.Z.S., Cunningham, D., Popescu, R.A., Solal-celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W.M., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti- CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated. Journal of Clinical Oncology, 18, 317-324.
6. Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., Link, B.K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N. & Radford, J. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111, 5486-5495.
7. Morschhauser, F.A., Cartron, G., Thieblemont, C., Solal-Céligny, P., Haioun, C., Bouabdallah, R., Feugier, P., Bouabdallah, K., Asikanius, E., Lei, G., Wenger, M., Wassner-Fritsch, E. & Salles, G.A. (2013) Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. Journal of Clinical Oncology, 31, 2912-2919.
8. Rule, S., Smith, P., Johnson, P.W., Bolam, S., Follows, G.A., Gambell, J., Hillmen, P., Jack, A., Johnson, S.A.N., Kirkwood, A., Kruger, A., Seymour, J.F., Toncheva, M., Walewski, J. & Linch, D.C. (2011) The addition of rituximab to fludarabine and cyclophosphamide (FC) chemotherapy improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the Randomised UK National Cancer Research Institute (NCRI) Trial. Blood: ASH Annual Meeting Abstracts, 118, abstr 440.
9. Teeling, J.L., Mackus, W.J.M., Wiegman, L.J.J.M., van den Brakel, J.H.N., Beers, S.a., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W.H.I., Glennie, M.J. & van de Winkel, J.G.J. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of immunology (Baltimore, Md.: 1950), 177, 362-371
10. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J.S., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of clinical oncology, 28, 1749-1755.